Published in PLoS One on October 14, 2010
Epidemiological characteristics of 2009 (H1N1) pandemic influenza based on paired sera from a longitudinal community cohort study. PLoS Med (2011) 2.26
Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med (2011) 1.46
The role of host genetics in susceptibility to influenza: a systematic review. PLoS One (2012) 1.39
Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS One (2011) 1.33
The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One (2011) 1.23
Case fatality risk of influenza A (H1N1pdm09): a systematic review. Epidemiology (2013) 1.21
Prevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida--November-December, 2009. PLoS One (2011) 1.15
Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One (2012) 1.13
Did modeling overestimate the transmission potential of pandemic (H1N1-2009)? Sample size estimation for post-epidemic seroepidemiological studies. PLoS One (2011) 1.12
Seroprevalence to influenza A(H1N1) 2009 virus--where are we? Clin Vaccine Immunol (2011) 1.11
Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One (2011) 1.04
Pandemic influenza due to pH1N1/2009 virus: estimation of infection burden in Reunion Island through a prospective serosurvey, austral winter 2009. PLoS One (2011) 1.03
Differential mortality rates by ethnicity in 3 influenza pandemics over a century, New Zealand. Emerg Infect Dis (2012) 0.97
The roles of competition and mutation in shaping antigenic and genetic diversity in influenza. PLoS Pathog (2013) 0.95
Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010. PLoS One (2011) 0.95
High incidence of severe influenza among individuals over 50 years of age. Clin Vaccine Immunol (2011) 0.94
Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age. PLoS One (2012) 0.92
Inferring influenza infection attack rate from seroprevalence data. PLoS Pathog (2014) 0.91
Cumulative incidence of pandemic influenza A (H1N1) 2009 by a community-based serological cohort study in Selenghe Province, Mongolia. Influenza Other Respir Viruses (2012) 0.91
The antigenic evolution of influenza: drift or thrift? Philos Trans R Soc Lond B Biol Sci (2013) 0.90
Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population. PLoS One (2013) 0.90
Sociodemographic factors and clinical conditions associated to hospitalization in influenza A (H1N1) 2009 virus infected patients in Spain, 2009-2010. PLoS One (2012) 0.89
Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. PLoS One (2011) 0.88
2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos. PLoS One (2013) 0.87
Evaluation of the seroprevalence of influenza A(H1N1) 2009 on a university campus: a cross-sectional study. BMC Public Health (2011) 0.86
Sero-prevalence and incidence of A/H1N1 2009 influenza infection in Scotland in winter 2009-2010. PLoS One (2011) 0.86
Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore. Emerg Infect Dis (2013) 0.85
Prevalence of antibodies against seasonal influenza A and B viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USA. PLoS Curr (2011) 0.84
A national study of individuals who handle migratory birds for evidence of avian and swine-origin influenza virus infections. J Clin Virol (2012) 0.83
Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France. PLoS One (2012) 0.82
Seropositivity for influenza A(H1N1)pdm09 virus among frontline health care personnel. Emerg Infect Dis (2013) 0.81
Estimating the disease burden of 2009 pandemic influenza A(H1N1) from surveillance and household surveys in Greece. PLoS One (2011) 0.77
The first cases of 2009 pandemic influenza A (H1N1) virus infection in the United States: a serologic investigation demonstrating early transmission. Influenza Other Respir Viruses (2012) 0.77
Seroepidemiologic study of pandemic (H1N1) 2009 during outbreak in boarding school, England. Emerg Infect Dis (2011) 0.77
The classical definition of a pandemic is not elusive. Bull World Health Organ (2011) 0.77
Self-diagnosis of influenza during a pandemic: a cross-sectional survey. BMJ Open (2011) 0.76
Pandemic influenza A(H1N1)pdm09: risk of infection in primary healthcare workers. Br J Gen Pract (2013) 0.76
Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis. Clin Transl Immunology (2014) 0.76
High rate of A(H1N1)pdm09 infections among rural Thai villagers, 2009-2010. PLoS One (2014) 0.76
Transmission of the First Influenza A(H1N1)pdm09 Pandemic Wave in Australia Was Driven by Undetected Infections: Pandemic Response Implications. PLoS One (2015) 0.75
Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance. Influenza Other Respir Viruses (2015) 0.75
The value of radiographic findings for the progression of pandemic 2009 influenza A/H1N1 virus infection. BMC Infect Dis (2013) 0.75
A humoral immunity survey following the 2012 influenza season after the pH1N1 pandemic in Guangzhou, China. Viral Immunol (2014) 0.75
Hospitalization risk of the 2009 H1N1 pandemic cases in Hong Kong. BMC Infect Dis (2014) 0.75
Rethinking thresholds for serological evidence of influenza virus infection. Influenza Other Respir Viruses (2017) 0.75
The Occupational Risk of Influenza A (H1N1) Infection among Healthcare Personnel during the 2009 Pandemic: A Systematic Review and Meta-Analysis of Observational Studies. PLoS One (2016) 0.75
School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program. Health Serv Res (2017) 0.75
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (2010) 12.43
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) (1972) 7.42
Determinants of immunity to influenza infection in man. Br Med Bull (1979) 4.62
Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ (2009) 4.31
Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill (2009) 4.23
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Update: swine influenza A (H1N1) infections--California and Texas, April 2009. MMWR Morb Mortal Wkly Rep (2009) 3.46
Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill (2009) 3.30
Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) (2003) 3.16
Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response. Br Med J (1972) 3.10
2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA (2010) 3.05
Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis (2009) 2.56
How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet (2009) 2.44
Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One (2010) 2.16
Transmissibility of 2009 pandemic influenza A(H1N1) in New Zealand: effective reproduction number and influence of age, ethnicity and importations. Euro Surveill (2010) 1.97
The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill (2009) 1.90
A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009. Aust N Z J Public Health (2010) 1.76
Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza viruses - New Zealand, 2009. MMWR Morb Mortal Wkly Rep (2009) 1.68
Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) (1977) 1.62
Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb Mortal Wkly Rep (2009) 1.58
Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza. PLoS Curr (2010) 1.57
Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J Chin Med Assoc (2010) 1.32
Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine. J Infect Dis (1977) 1.25
An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness. Am J Epidemiol (1974) 1.18
Immunity to challenge in volunteers vaccinated with an inactivated current or earlier strain of influenza A(H3N2). J Hyg (Lond) (1978) 1.01
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy (2004) 13.16
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis (2012) 8.02
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax (2007) 4.67
Degeneration of the intervertebral disc. Arthritis Res Ther (2003) 4.30
A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. J Bone Joint Surg Am (2007) 3.73
Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am (2004) 3.59
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. N Engl J Med (2015) 3.57
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet (2003) 3.52
The etiology of diagnostic errors: a controlled trial of system 1 versus system 2 reasoning. Acad Med (2014) 3.48
Tiotropium Respimat increases the risk of mortality. Thorax (2013) 3.34
Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet (2005) 3.01
Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses. Influenza Other Respir Viruses (2009) 2.75
PHARMAC and tobacco control in New Zealand: government policy 'up in smoke'. N Z Med J (2005) 2.54
Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck (2012) 2.40
A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. Basic Res Cardiol (2012) 2.37
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol (2009) 2.25
Histological assessment of cartilage repair: a report by the Histology Endpoint Committee of the International Cartilage Repair Society (ICRS). J Bone Joint Surg Am (2003) 2.24
MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine (2005) 2.20
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust (2009) 2.16
Limited generalisability of UPLIFT findings to clinical practice. Thorax (2013) 2.15
Corynebacterium species isolated from patients with mastitis. Clin Infect Dis (2002) 2.12
Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax (2011) 2.11
Buteyko pseudoscience. N Z Med J (2004) 2.02
A new histology scoring system for the assessment of the quality of human cartilage repair: ICRS II. Am J Sports Med (2010) 1.93
British National Formulary for Children: the risk of inappropriate paracetamol prescribing. Arch Dis Child (2011) 1.88
Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. Ann Allergy Asthma Immunol (2004) 1.84
Effects of cannabis on pulmonary structure, function and symptoms. Thorax (2007) 1.79
Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J Allergy Clin Immunol (2012) 1.78
Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis. Arthritis Res Ther (2012) 1.74
External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax (2006) 1.72
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambia. PLoS One (2010) 1.71
Estimating the reproduction number of the novel influenza A virus (H1N1) in a Southern Hemisphere setting: preliminary estimate in New Zealand. N Z Med J (2009) 1.70
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med (2013) 1.66
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma. Respirology (2014) 1.64
How to write research papers and grants: 2011 Asian Pacific Society for Respirology Annual Scientific Meeting Postgraduate Session. Respirology (2012) 1.58
Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest (2005) 1.57
Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med (2007) 1.56
Tissue engineering and the intervertebral disc: the challenges. Eur Spine J (2008) 1.56
Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther (2004) 1.55
Ayurvedic medicine: patients in peril from plumbism. N Z Med J (2006) 1.55
The New Zealand national junior doctors' strike: implications for the provision of acute hospital medical services. Clin Med (2008) 1.53
Increasing the uptake of opportunistic chlamydia screening: a pilot study in general practice. J Prim Health Care (2010) 1.52
The all-age spirometry reference ranges reflect contemporary Australasian spirometry. Respirology (2011) 1.52
Complete reference ranges for pulmonary function tests from a single New Zealand population. N Z Med J (2006) 1.52
Transmission of pandemic A/H1N1 2009 influenza on passenger aircraft: retrospective cohort study. BMJ (2010) 1.52
Tiotropium Respimat increases the risk of mortality: pro. Eur Respir J (2013) 1.51
Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis (2003) 1.49
Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital. Thorax (2007) 1.49
Cells from different regions of the intervertebral disc: effect of culture system on matrix expression and cell phenotype. Spine (Phila Pa 1976) (2002) 1.48
Do natural health food stores require regulation? N Z Med J (2002) 1.47
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J (2005) 1.46
Pilot study of the safety and effect of intranasal delipidated acid-treated Mycobacterium vaccae in adult asthma. Respirology (2003) 1.46
Is it time to change the approach to oxygen therapy in the breathless patient? Thorax (2007) 1.45
Increased nerve and blood vessel ingrowth associated with proteoglycan depletion in an ovine anular lesion model of experimental disc degeneration. Spine (Phila Pa 1976) (2002) 1.39
The excess cost associated with healthcare-associated bloodstream infections at Auckland City Hospital. N Z Med J (2010) 1.39
Elastic fibre organization in the intervertebral discs of the bovine tail. J Anat (2002) 1.38
Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem (2006) 1.38
COX-2 inhibitors--first, do no harm. N Z Med J (2005) 1.38
Microfibrils, elastin fibres and collagen fibres in the human intervertebral disc and bovine tail disc. J Anat (2007) 1.38
High blood pressure advice given by natural health food stores. N Z Med J (2009) 1.38
Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci (2003) 1.31
External validity of randomized controlled trials in COPD. Respir Med (2006) 1.30
The elastic fiber network of the anulus fibrosus of the normal and scoliotic human intervertebral disc. Spine (Phila Pa 1976) (2005) 1.29
Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin (2007) 1.29
Microfracture for acetabular chondral defects in patients with femoroacetabular impingement: results at second-look arthroscopic surgery. Am J Sports Med (2012) 1.29
Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med (2012) 1.29
Foods and dietary patterns that are healthy, low-cost, and environmentally sustainable: a case study of optimization modeling for New Zealand. PLoS One (2013) 1.26
Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. Am J Infect Control (2010) 1.22
Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust (2011) 1.22
The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J R Soc Med (2010) 1.21
Evaluation of rapid and simple techniques for the enrichment of viruses prior to metagenomic virus discovery. J Virol Methods (2013) 1.21
Mortality risk factors for pandemic influenza on New Zealand troop ship, 1918. Emerg Infect Dis (2010) 1.21
Marked campylobacteriosis decline after interventions aimed at poultry, New Zealand. Emerg Infect Dis (2011) 1.21
Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol (2008) 1.20
The influence of serum, glucose and oxygen on intervertebral disc cell growth in vitro: implications for degenerative disc disease. Arthritis Res Ther (2008) 1.20
Screening for influenza infection in international airline travelers. Am J Public Health (2009) 1.20
Epidemiologic and virologic assessment of the 2009 influenza A (H1N1) pandemic on selected temperate countries in the Southern Hemisphere: Argentina, Australia, Chile, New Zealand and South Africa. Influenza Other Respir Viruses (2011) 1.19
Physiological associations of computerized tomography lung density: a factor analysis. Int J Chron Obstruct Pulmon Dis (2006) 1.18
Arterial oxygen tension and mortality in mechanically ventilated patients. Intensive Care Med (2011) 1.17
The use of the self-management plan system of care in adult asthma. Prim Care Respir J (2004) 1.17
Seasonality in human zoonotic enteric diseases: a systematic review. PLoS One (2012) 1.17
Honey in the treatment of burns: a systematic review and meta-analysis of its efficacy. N Z Med J (2009) 1.16
Border control measures in the influenza pandemic plans of six South Pacific nations: a critical review. N Z Med J (2008) 1.16
Prolonged work- and computer-related seated immobility and risk of venous thromboembolism. J R Soc Med (2010) 1.15
Emergence of echovirus type 13 as a prominent enterovirus. Clin Infect Dis (2003) 1.13
Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. Carcinogenesis (2002) 1.12
Quarantine for pandemic influenza control at the borders of small island nations. BMC Infect Dis (2009) 1.12
The Global Lung Initiative 2012 reference values reflect contemporary Australasian spirometry. Respirology (2012) 1.11
Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Res (2009) 1.11
Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years. J Med Virol (2006) 1.10
Thermal image scanning for influenza border screening: results of an airport screening study. PLoS One (2011) 1.10
The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J (2004) 1.10
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis (2010) 1.09
Autologous chondrocyte implantation with bone grafting for osteochondral defect due to posttraumatic osteonecrosis of the hip--a case report. Acta Orthop (2006) 1.09
The association between SpO2 values and mortality--interpret with caution. Resuscitation (2012) 1.08
From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine (2005) 1.07